Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
6.85
+0.09 (1.33%)
Aug 13, 2025, 3:57 PM - Market open
Tango Therapeutics Revenue
Tango Therapeutics had revenue of $3.18M in the quarter ending June 30, 2025, a decrease of -83.99%. This brings the company's revenue in the last twelve months to $24.30M, down -42.85% year-over-year. In the year 2024, Tango Therapeutics had annual revenue of $42.07M with 15.17% growth.
Revenue (ttm)
$24.30M
Revenue Growth
-42.85%
P/S Ratio
30.64
Revenue / Employee
$156,748
Employees
155
Market Cap
762.13M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 42.07M | 5.54M | 15.17% |
Dec 31, 2023 | 36.53M | 11.67M | 46.93% |
Dec 31, 2022 | 24.86M | -12.18M | -32.89% |
Dec 31, 2021 | 37.04M | 29.39M | 383.83% |
Dec 31, 2020 | 7.66M | -16.99M | -68.94% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
TNGX News
- 8 days ago - Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewsWire
- 6 weeks ago - Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer - GlobeNewsWire
- 2 months ago - Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors - GlobeNewsWire
- 3 months ago - Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewsWire
- 3 months ago - Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - GlobeNewsWire
- 5 months ago - Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 - GlobeNewsWire
- 5 months ago - Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights - GlobeNewsWire